---
schema_version: "secwatch.filing_event.v1"
accession: "0001753926-23-000298"
form_type: "8-K"
ticker: "VANI"
cik: "0001266806"
company_name: "Vivani Medical, Inc."
filed_at: "2023-03-21T23:59:59+00:00"
generated_at: "2026-06-17T22:00:40.307339+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Vivani Medical subsidiary Cortigent files for IPO; Vivani to fund ops until offering

## Summary
- Cortigent, Vivani's neuromodulation subsidiary, filed S-1 for IPO; ThinkEquity sole book-runner.
- Vivani agrees to fund Cortigent salaries, rent, overhead until Dec 31, 2024 or IPO close.
- Cortigent must repay all advanced funds plus accrued interest after funding support term.
- Cortigent will be controlled by Vivani post-IPO, led by CEO Jonathan Adams.
- IPO subject to market conditions; no assurance of completion or terms.

## SEC filing metadata
- accession: 0001753926-23-000298
- form_type: 8-K
- ticker: VANI
- cik: 0001266806
- company_name: Vivani Medical, Inc.
- filed_at: 2023-03-21T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1266806/000175392623000298/0001753926-23-000298-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1266806/000175392623000298/g083455_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001753926-23-000298
- JSON: https://secwatch.observer/filing/0001753926-23-000298.json
- Plain text: https://secwatch.observer/filing/0001753926-23-000298.txt

## Key facts
- Material Agreements
  Vivani Medical, Inc. entered into Transition Funding, Support and Services Agreement with Cortigent, Inc. (effective 2023-03-19).
  - Action: entry
  - Counterparty: Cortigent, Inc.
  - Effective: 2023-03-19
  source text: On March 19, 2023, the Company and Cortigent, Inc. (“Cortigent”), a wholly owned subsidiary of the Company entered into a Transition Funding, Support and Services Agreement (the “TFSSA”), pursuant to which the Company has agreed to advance funds and provide or cause to be provided to Cortigent the services and funding intended to cover salaries and related costs, rent and other overhead in order to permit Cortigent to operate in substantially the same manner in which business operations of Cortigent were previously operated by Second Sight Medical Products, Inc., prior to the formation of Cortigent, which obligations will continue, in the case of the funding obligations, until the earlier of December 31, 2024 or the closing of an initial public offering of Cortigent (the "Funding Support Term").
  evidence_url: https://www.sec.gov/Archives/edgar/data/1266806/000175392623000298/0001753926-23-000298-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.